Valuation Spero Therapeutics, Inc. Börse Stuttgart
Stocks
2HA
US84833T1034
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
After hours 16:00:05 | |||
| 1.148 EUR | +4.27% |
|
1.028 | -10.45% |
Company Valuation: Spero Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 517.5 | 89.57 | 77.91 | 56.15 | 131.3 | 73.53 | - |
| Change | - | -82.69% | -13.02% | -27.92% | 133.77% | -43.98% | - |
| Enterprise Value (EV) | 371.1 | 89.57 | 77.91 | 56.15 | 131.3 | 73.53 | 73.53 |
| Change | - | -75.86% | -13.02% | -27.92% | 133.77% | -43.98% | 0% |
| P/E | -5.5x | -1.41x | 3.42x | -0.81x | 15.5x | -4.38x | 1.9x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | 0x | -0x | 0x | -0x | 0x | -0x |
| Capitalization / Revenue | 28,346,906x | 1,673,972x | 750,706x | 1,170,430x | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -2.91 | -1.23 | 0.43 | -1.27 | 0.15 | -0.29 | 0.67 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales | 18.26 | 53.51 | 103.8 | 47.98 | - | - | - |
| EBITDA | -87.32 | - | - | - | - | - | - |
| EBIT | -87.97 | -42.2 | 21.48 | -73.36 | - | - | - |
| Net income | -89.76 | -46.42 | 22.81 | -68.57 | - | - | - |
| Net Debt | -146.4 | - | - | - | - | - | - |
| Reference price 2 | 16.010 | 1.730 | 1.470 | 1.030 | 2.330 | 1.270 | 1.270 |
| Nbr of stocks (in thousands) | 32,324 | 51,776 | 52,999 | 54,518 | 56,339 | 57,901 | - |
| Announcement Date | 3/31/22 | 3/30/23 | 3/13/24 | 3/27/25 | 3/26/26 | - | - |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.83x | 6.36x | 13.92x | 1.53% | 55.27B | |
| 32.72x | 8.17x | 25.61x | 0.05% | 54.15B | |
| -41.75x | 13.26x | -39.07x | -.--% | 23.11B | |
| -18.34x | 4.38x | -7.67x | -.--% | 23.22B | |
| 25.44x | 5.01x | 13.23x | -.--% | 20.33B | |
| 24.96x | 4.84x | 15.73x | -.--% | 17.91B | |
| -612.56x | 37.5x | -1557.05x | -.--% | 15.76B | |
| 45.31x | 18.35x | 47.24x | 0.08% | 15B | |
| 17.3x | 5.01x | 11.68x | -.--% | 13.82B | |
| Average | -56.23x | 11.43x | -164.04x | 0.18% | 26.51B | |
| Weighted average by Cap. | -26.16x | 9.75x | -92.41x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRO Stock
- 2HA Stock
- Valuation Spero Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
